Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.

BMC cancer - 12 May 2020

Wagener-Ryczek Svenja, Heydt Carina, Süptitz Juliane, Michels Sebastian, Falk Markus, Alidousty Christina, Fassunke Jana, Ihle Michaela Angelika, Tiemann Markus, Heukamp Lukas, Wolf Jürgen, Büttner Reinhard, Merkelbach-Bruse Sabine

Abstract excerpt

BACKGROUND: Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd -generation irreversible EGFR TKI Afatinib were aimed to improve treatment response. Nevertheless, diverse resistance mechanisms develop within the first year of therapy. Here, we evaluate the prevalence of acquired resistance mechanisms towards...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Follow-Up Studies

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 32397977
DOI: 10.1186/s12885-020-06920-3
PMCID: PMC7216404

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.PMID 32397977Read ↗

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.Semantic proximity Read ↗

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitorsSemantic proximity Read ↗

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Semantic proximity Read ↗

Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.Semantic proximity Read ↗

Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.Semantic proximity Read ↗

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.Semantic proximity Read ↗

Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR.Semantic proximity Read ↗

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC.Semantic proximity Read ↗

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.Semantic proximity Read ↗

Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistanceSemantic proximity Read ↗

Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.